Last Price$59.76.8%
Market Cap$3,532.4M
LTM NOPAT
$249.0M
NOPAT margin
57.3%
5Y avg: (1,176.8%)
EPV as % of EV
113.7%
Market-Implied Value of Growth,
MIVoG as % of EV
(13.7%)
Discount rate
11.4%
Stock quality
7/10
Great
PTGX Earnings Power Value Model
| (USD M) | Mar'20 | Jun'20 | Sep'20 | Dec'20 | Mar'21 | Jun'21 | Sep'21 | Dec'21 | Mar'22 | Jun'22 | Sep'22 | Dec'22 | Mar'23 | Jun'23 | Sep'23 | Dec'23 | Mar'24 | Jun'24 | Sep'24 | Dec'24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LTM Revenue % growth | 2.3 (89.3%) | 16.7 808.4% | 25.7 N/A | 28.6 12,293.1% | 31.2 1,244.7% | 27.2 62.7% | 24.4 (5.1%) | 27.4 (4.4%) | 46.9 50.4% | 45.5 67.1% | 35.2 44.3% | 26.6 (2.8%) | 0.9 (98.2%) | 0.0 (100.0%) | 0.0 (100.0%) | 60.0 125.7% | 315.0 36,565.1% | 319.1 N/A | 323.8 N/A | 434.4 624.1% |
LTM NOPAT % growth | (84.9) N/A | (74.5) (12.2%) | (65.1) (12.6%) | (64.5) (1.0%) | (68.5) 6.3% | (80.0) 16.7% | (106.3) 32.9% | (125.0) 17.5% | (122.0) (2.4%) | (132.2) 8.4% | (129.3) (2.1%) | (126.7) (2.1%) | (139.3) 10.0% | (136.3) (2.2%) | (142.4) 4.5% | (80.3) (43.6%) | 153.8 N/A | 154.4 0.4% | 150.8 (2.3%) | 249.0 65.1% |
Discount rate | 7.1% | 7.4% | 7.5% | 7.8% | 8.6% | 8.4% | 8.4% | 8.4% | 9.2% | 9.9% | 10.6% | 10.7% | 10.4% | 10.7% | 11.5% | 10.8% | 11.2% | 11.3% | 10.6% | 11.4% |
| Earnings Power Value (EPV) | (1,199.2) | (1,011.3) | (866.1) | (829.8) | (797.5) | (956.5) | (1,266.3) | (1,490.2) | (1,325.4) | (1,335.8) | (1,218.7) | (1,184.2) | (1,337.4) | (1,270.3) | (1,242.2) | (745.6) | 1,376.8 | 1,371.3 | 1,422.1 | 2,184.9 |
Enterprise Value (EV) | 83.9 | 470.9 | 556.4 | 605.4 | 819.5 | 1,712.2 | 495.7 | 1,343.3 | 843.3 | 96.6 | 117.9 | 276.7 | 903.7 | 1,345.9 | 678.7 | 1,067.5 | 1,421.2 | 1,786.5 | 2,178.7 | 1,920.9 |
| Market-Implied Value of Growth (MIVoG) | 1,283.1 | 1,482.2 | 1,422.5 | 1,435.2 | 1,617.0 | 2,668.7 | 1,762.0 | 2,833.4 | 2,168.6 | 1,432.4 | 1,336.6 | 1,460.9 | 2,241.1 | 2,616.2 | 1,920.8 | 1,813.2 | 44.4 | 415.2 | 756.7 | (264.0) |
| EPV as % of EV | (1,429.5%) | (214.7%) | (155.7%) | (137.1%) | (97.3%) | (55.9%) | (255.5%) | (110.9%) | (157.2%) | (1,383.3%) | (1,034.1%) | (428.0%) | (148.0%) | (94.4%) | (183.0%) | (69.8%) | 96.9% | 76.8% | 65.3% | 113.7% |
| MIVoG as % of EV | 1,529.5% | 314.7% | 255.7% | 237.1% | 197.3% | 155.9% | 355.5% | 210.9% | 257.2% | 1,483.3% | 1,134.1% | 528.0% | 248.0% | 194.4% | 283.0% | 169.8% | 3.1% | 23.2% | 34.7% | (13.7%) |
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
PTGX NOPAT
Annual
Quarterly
LTM
PTGX Earnings Power Value and Enterprise Value
Annual
LTM
Enterprise Value Breakdown
EPV and MIVoG as % of EV
PTGX vs Peer Set: Earnings Power Value comparison
General
Earnings power value
Financial metrics
Company name
EPV as % of EV
MIVoG as % of EV
Revenue growth
EPS growth
Net income margin
Protagonist Therapeutics, Inc.PTGX
113.7%
(13.7%)
624.1%
N/A
63.3%
Median Peer Set
0.6%
99.4%
18.0%
(38.6%)
15.0%
Royalty Pharma plcRPRX
121.4%
(21.4%)
(3.8%)
(43.7%)
37.9%
United Therapeutics CorporationUTHR
107.6%
(7.6%)
23.6%
25.7%
41.5%
Regeneron Pharmaceuticals, Inc.REGN
71.7%
28.3%
8.3%
10.4%
31.1%
BioMarin Pharmaceutical Inc.BMRN
40.2%
59.8%
18.0%
139.3%
15.0%
Vertex Pharmaceuticals IncorporatedVRTX
7.1%
92.9%
11.7%
N/A
(4.9%)
Alnylam Pharmaceuticals, Inc.ALNY
(6.0%)
106.0%
23.0%
(38.6%)
(12.4%)
argenx SEARGX
(12.2%)
112.2%
198.6%
(60.5%)
(24.1%)
Summit Therapeutics Inc.SMMT
(21.9%)
121.9%
N/A
(68.7%)
N/A
BioNTech SEBNTX
(176.1%)
276.1%
(77.4%)
(89.7%)
24.4%
BeiGene, Ltd.BGNE
(8,818.5%)
8,918.5%
73.7%
467.1%
(35.9%)
Explore more intrinsic value tools hub for PTGX
Reverse DCF
Intrinsic Value
Peter Lynch Fair Value
Discount rate
Earnings growth model
Relative Value
DCF value calculator
Ben Graham Fair Value
Peter Lynch charts
Margin of safety
FAQ
What is Protagonist Therapeutics, Inc. Earnings Power Value?
As of Dec 31, 2024, Protagonist Therapeutics, Inc.'s Earnings Power Value is approximately $2,184.9M.
What is Protagonist Therapeutics, Inc. EV (Enterprise Value)?
As of Dec 31, 2024, Protagonist Therapeutics, Inc.'s Enterprise Value (EV) estimates at $1,920.9M.
What is Protagonist Therapeutics, Inc. NOPAT?
As of Dec 31, 2024, Protagonist Therapeutics, Inc.'s Net operating profit after tax (NOPAT) is approximately $249.0M.